TG Therapeutics, Inc. (TGTX) CEO Mike Weiss on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/02/21
TG Therapeutics Stock Plunged As H.C. Wainwright Cuts Target Price After Disappointing Q2Benzinga • 08/02/21
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/02/21
TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business UpdateGlobeNewsWire • 07/28/21
TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare ConferenceGlobeNewsWire • 07/09/21
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021Seeking Alpha • 07/06/21
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of NeurologyGlobeNewsWire • 06/18/21
TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant LymphomaGlobeNewsWire • 06/18/21
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual CongressGlobeNewsWire • 06/11/21
TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant LymphomaGlobeNewsWire • 06/09/21
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 06/04/21
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaGlobeNewsWire • 05/25/21
TG Therapeutics' (TGTX) CEO Mike Weiss on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21